Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 541927, 7 pages
http://dx.doi.org/10.1155/2010/541927
Review Article

Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

1Molecular Genetics Unit, G. Gaslini Institute, 16147 Genova, Italy
2Department of Pediatrics, Center of Excellence for Biomedical Research (CEBR), University of Genova, 16147 Genova, Italy

Received 9 March 2010; Accepted 19 April 2010

Academic Editor: Beata Lecka-Czernik

Copyright © 2010 Renata Bocciardi and Roberto Ravazzolo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. S. Kaplan and R. M. Smith, “Clinical vignette fibrodysplasia ossificans progressiva (FOP),” Journal of Bone and Mineral Research, vol. 12, no. 5, p. 855, 1997. View at Google Scholar · View at Scopus
  2. F. S. Kaplan, Q. Shen, V. Lounev et al., “Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP),” Journal of Bone and Mineral Metabolism, vol. 26, no. 6, pp. 521–530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. S. Kaplan, M. Le Merrer, D. L. Glaser et al., “Fibrodysplasia ossificans progressiva,” Best Practice and Research Clinical Rheumatology, vol. 22, no. 1, pp. 191–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. E. M. Shore, M. Xu, G. J. Feldman, D. A. Fenstermacher, M. A. Brown, and F. S. Kaplan, “A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva,” Nature Genetics, vol. 38, no. 5, pp. 525–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. F. S. Kaplan, M. Xu, P. Seemann et al., “Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1,” Human Mutation, vol. 30, no. 3, pp. 379–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Bocciardi, D. Bordo, M. Di Duca, M. Di Rocco, and R. Ravazzolo, “Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements,” European Journal of Human Genetics, vol. 17, no. 3, pp. 311–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Fukuda, M. Kohda, K. Kanomata et al., “Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva,” Journal of Biological Chemistry, vol. 284, no. 11, pp. 7149–7156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Q. Shen, S. C. Little, M. Xu et al., “The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization,” Journal of Clinical Investigation, vol. 119, no. 11, pp. 3462–3472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. van Dinther, N. Visser, D. J. de Gorter et al., “ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation,” Journal of Bone Mineral Research, vol. 25, no. 6, pp. 1208–1215, 2010. View at Google Scholar
  10. F. S. Kaplan, J. A. Tabas, F. H. Gannon, G. Finkel, G. V. Hahn, and M. A. Zasloff, “The histopathology of fibrodysplasia ossificans progressiva. An endochondral process,” Journal of Bone and Joint Surgery, vol. 75, no. 2, pp. 220–230, 1993. View at Google Scholar · View at Scopus
  11. F. H. Gannon, F. S. Kaplan, E. Olmsted, G. C. Finkel, M. A. Zasloff, and E. Shore, “Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva,” Human Pathology, vol. 28, no. 3, pp. 339–343, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. F. H. Gannon, B. A. Valentine, E. M. Shore, M. A. Zasloff, and F. S. Kaplan, “Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva,” Clinical Orthopaedics and Related Research, no. 346, pp. 19–25, 1998. View at Google Scholar · View at Scopus
  13. F. H. Gannon, D. Glaser, R. Caron, L. D. R. Thompson, E. M. Shore, and F. S. Kaplan, “Mast cell involvement in fibrodysplasia ossificans progressiva,” Human Pathology, vol. 32, no. 8, pp. 842–848, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Pignolo, R. K. Suda, and F. S. Kaplan, “The fibrodysplasia ossificans progressiva lesion,” Clinical Reviews in Bone and Mineral Metabolism, vol. 3, no. 3-4, pp. 195–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. S. Kaplan, C. M. Strear, and M. A. Zasloff, “Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva,” Clinical Orthopaedics and Related Research, no. 304, pp. 238–247, 1994. View at Google Scholar · View at Scopus
  16. D. Gatti, O. Viapiana, M. Rossini et al., “Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressive,” Journal of Bone Mineral Research, vol. 25, no. 6, pp. 1460–1462, 2010. View at Google Scholar
  17. N. Cho and Y. Momose, “Peroxisome proliferator-activated receptor γ agonists as insulin sensitizers: from the discovery to recent progress,” Current Topics in Medicinal Chemistry, vol. 8, no. 17, pp. 1483–1507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. G. Kalaitzidis, P. A. Sarafidis, and G. L. Bakris, “Effects of thiazolidinediones beyond glycaemic control,” Current Pharmaceutical Design, vol. 15, no. 5, pp. 529–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  20. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Diradourian, J. Girard, and J.-P. Pégorier, “Phosphorylation of PPARs: from molecular characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Varin and S. Gordon, “Alternative activation of macrophages: immune function and cellular biology,” Immunobiology, vol. 214, no. 7, pp. 630–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. McClelland, R. Shrivastava, and J. D. Medh, “Regulation of translational efficiency by disparate 5-UTRs of PPAR splice variants,” PPAR Research, Article ID 193413, 8 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. J. Ko, Y. S. Kang, S. Y. Han et al., “Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2750–2760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Martin, “Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components,” Mutation Research, vol. 669, no. 1-2, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Google Scholar · View at Scopus
  27. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Gosset, A.-S. Charbonnier, P. Delerive et al., “Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells,” European Journal of Immunology, vol. 31, no. 10, pp. 2857–2865, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Faveeuw, S. Fougeray, V. Angeli et al., “Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells,” FEBS Letters, vol. 486, no. 3, pp. 261–266, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al., “Macrophage-specific PPARγ controls alternative activation and improves insulin resistance,” Nature, vol. 447, no. 7148, pp. 1116–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. V. R. Narala, R. Ranga, M. R. Smith et al., “Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma,” Respiratory Research, vol. 8, p. 90, 2007. View at Google Scholar · View at Scopus
  34. M. Koufany, D. Moulin, A. Bianchi et al., “Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis,” Arthritis Research and Therapy, vol. 10, no. 1, article R6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. J. Bright, C. C. Walline, S. Kanakasabai, and S. Chakraborty, “Targeting PPAR as a therapy to treat multiple sclerosis,” Expert Opinion on Therapeutic Targets, vol. 12, no. 12, pp. 1565–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. D. Lewis, G. R. Lichtenstein, R. B. Stein et al., “An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis,” American Journal of Gastroenterology, vol. 96, no. 12, pp. 3323–3328, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. J. D. Lewis, G. R. Lichtenstein, J. J. Deren et al., “Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial,” Gastroenterology, vol. 134, no. 3, pp. 688–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. E. H. Jeninga, M. Gurnell, and E. Kalkhoven, “Functional implications of genetic variation in human PPARγ,” Trends in Endocrinology and Metabolism, vol. 20, no. 8, pp. 380–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Klotz, S. Schmidt, R. Heun, T. Klockgether, and H. Kölsch, “Association of the PPARγ gene polymorphism Pro12Ala with delayed onset of multiple sclerosis,” Neuroscience Letters, vol. 449, no. 1, pp. 81–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. J. Regieli, J. W. Jukema, P. A. Doevendans et al., “PPARγ variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients,” Diabetes Care, vol. 32, no. 5, pp. 839–844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ,” Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. K. W. Park, D. S. Halperin, and P. Tontonoz, “Before they were fat: adipocyte progenitors,” Cell Metabolism, vol. 8, no. 6, pp. 454–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Kubota, Y. Terauchi, H. Miki et al., “PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Akune, S. Ohba, S. Kamekura et al., “PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. T.-A. Cock, J. Back, F. Elefteriou et al., “Enhanced bone formation in lipodystrophic PPARγ(hyp/hyp) mice relocates haematopoiesis to the spleen,” EMBO Reports, vol. 5, no. 10, pp. 1007–1012, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. C. B. Confavreux, R. L. Levine, and G. Karsenty, “A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms,” Molecular and Cellular Endocrinology, vol. 310, no. 1-2, pp. 21–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Wan, L.-W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” Nature Medicine, vol. 13, no. 12, pp. 1496–1503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” Endocrinology, vol. 145, no. 1, pp. 401–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” Endocrinology, vol. 146, no. 3, pp. 1226–1235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Viberti, S. E. Kahn, D. A. Greene et al., “A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes,” Diabetes Care, vol. 25, no. 10, pp. 1737–1743, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. S. E. Kahn, B. Zinman, J. M. Lachin et al., “Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT),” Diabetes Care, vol. 31, no. 5, pp. 845–851, 2008. View at Google Scholar
  53. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” The Lancet, vol. 373, no. 9681, pp. 2125–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. I. J. Douglas, S. J. Evans, S. Pocock, and L. Smeeth, “The risk of fractures associated with thiazolidinediones: a self-controlled case-series study,” PLoS Medicine, vol. 6, no. 9, Article ID e1000154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. G. Jones, S. R. Momin, M. W. Good, T. K. Shea, and K. Patric, “Distal upper and lower limb fractures associated with thiazolidinedione use,” American Journal of Managed Care, vol. 15, no. 8, pp. 491–496, 2009. View at Google Scholar · View at Scopus
  56. B. Zinman, S. M. Haffner, W. H. Herman et al., “Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 134–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. F. S. Kaplan, D. L. Glaser, E. M. Shore et al., “Hematopoietic stem-cell contribution to ectopic skeletogenesis,” Journal of Bone and Joint Surgery, vol. 89, no. 2, pp. 347–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. V. Y. Lounev, R. Ramachandran, M. N. Wosczyna et al., “Identification of rogenitor cells that contribute to eterotopic skeletogenesis,” Journal of Bone and Joint Surgery A, vol. 91, no. 3, pp. 652–663, 2009. View at Publisher · View at Google Scholar · View at Scopus